DK169422B1 - Anvendelse af heparin, N-desulfateret, N-acetyleret heparin eller O-desulfateret, N-acetyleret heparin til fremstilling af et farmaceutisk præparat, som er effektivt over for autoimmune sygdomme, til lindring af sådanne sygdomme og til behandling af autoimmune sygdomme i pattedyr, herunder mennesker, og til hindring eller forsinkelse af allotransplantatudstødelse - Google Patents

Anvendelse af heparin, N-desulfateret, N-acetyleret heparin eller O-desulfateret, N-acetyleret heparin til fremstilling af et farmaceutisk præparat, som er effektivt over for autoimmune sygdomme, til lindring af sådanne sygdomme og til behandling af autoimmune sygdomme i pattedyr, herunder mennesker, og til hindring eller forsinkelse af allotransplantatudstødelse Download PDF

Info

Publication number
DK169422B1
DK169422B1 DK331287A DK331287A DK169422B1 DK 169422 B1 DK169422 B1 DK 169422B1 DK 331287 A DK331287 A DK 331287A DK 331287 A DK331287 A DK 331287A DK 169422 B1 DK169422 B1 DK 169422B1
Authority
DK
Denmark
Prior art keywords
heparin
desulfated
acetylated
dose
autoimmune diseases
Prior art date
Application number
DK331287A
Other languages
Danish (da)
English (en)
Other versions
DK331287A (da
DK331287D0 (da
Inventor
Irun Cohen
Israel Vlodavsky
Amiram Eldor
Yaakov Naparstek
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of DK331287D0 publication Critical patent/DK331287D0/da
Publication of DK331287A publication Critical patent/DK331287A/da
Application granted granted Critical
Publication of DK169422B1 publication Critical patent/DK169422B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Soil Working Implements (AREA)
  • Paper (AREA)
  • Fertilizers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK331287A 1986-06-26 1987-06-26 Anvendelse af heparin, N-desulfateret, N-acetyleret heparin eller O-desulfateret, N-acetyleret heparin til fremstilling af et farmaceutisk præparat, som er effektivt over for autoimmune sygdomme, til lindring af sådanne sygdomme og til behandling af autoimmune sygdomme i pattedyr, herunder mennesker, og til hindring eller forsinkelse af allotransplantatudstødelse DK169422B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL79254A IL79254A0 (en) 1986-06-26 1986-06-26 Compositions for preventing graft rejection
IL7925486 1986-06-26

Publications (3)

Publication Number Publication Date
DK331287D0 DK331287D0 (da) 1987-06-26
DK331287A DK331287A (da) 1987-12-27
DK169422B1 true DK169422B1 (da) 1994-10-31

Family

ID=11056896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK331287A DK169422B1 (da) 1986-06-26 1987-06-26 Anvendelse af heparin, N-desulfateret, N-acetyleret heparin eller O-desulfateret, N-acetyleret heparin til fremstilling af et farmaceutisk præparat, som er effektivt over for autoimmune sygdomme, til lindring af sådanne sygdomme og til behandling af autoimmune sygdomme i pattedyr, herunder mennesker, og til hindring eller forsinkelse af allotransplantatudstødelse

Country Status (10)

Country Link
EP (1) EP0251134B1 (de)
JP (1) JP2527749B2 (de)
AT (1) ATE82502T1 (de)
AU (1) AU608228B2 (de)
DE (1) DE3782686T2 (de)
DK (1) DK169422B1 (de)
ES (1) ES2052514T3 (de)
GR (1) GR3006814T3 (de)
IL (1) IL79254A0 (de)
NO (1) NO872675L (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
IL86753A0 (en) * 1988-06-15 1988-11-30 Hadassah Med Org Pharmaceutical compositions for treatment of lupus
DE3821271A1 (de) * 1988-06-23 1989-12-28 Solco Basel Ag Derivatisiertes heparin, verfahren zu dessen herstellung und arzneimittel, welches dieses enthaelt
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
EP0998941B9 (de) * 1997-07-14 2007-03-14 Takashi Muramatsu Verwendung von midkin oder von anti-midkin antikörper
US6538028B1 (en) 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
CN1197587C (zh) * 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
KR100855331B1 (ko) 2001-09-12 2008-09-04 시그마타우 리서치 스위츠랜드 에스.에이 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체
RU2347574C2 (ru) 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
AU2009284393B2 (en) 2008-08-22 2014-09-25 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders
CA2786758A1 (en) 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
DK2734213T3 (en) 2011-07-19 2018-08-13 Baxalta GmbH RESORPTION PROMOTERS ADDITIVES TO IMPROVE ORAL FORMULATION OF NON-ANTI-COATING SULPHATE POLYSACCHARIDS
WO2014028382A1 (en) 2012-08-14 2014-02-20 Baxter International Inc. Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
EP2968400B1 (de) 2013-03-12 2019-05-08 Baxalta GmbH Resorptionsförderer als additive zur verbesserung der oralen formulierung von niedermolekularen heparinen
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
CA2986974C (en) * 2015-06-11 2023-08-15 Universiteit Maastricht Method for preventing transplant failure in a host

Also Published As

Publication number Publication date
EP0251134B1 (de) 1992-11-19
DE3782686T2 (de) 1993-06-09
NO872675L (no) 1987-12-28
JPS6388127A (ja) 1988-04-19
JP2527749B2 (ja) 1996-08-28
GR3006814T3 (de) 1993-06-30
EP0251134A2 (de) 1988-01-07
IL79254A0 (en) 1986-09-30
DK331287A (da) 1987-12-27
ES2052514T3 (es) 1994-07-16
DE3782686D1 (de) 1992-12-24
DK331287D0 (da) 1987-06-26
AU7470687A (en) 1988-01-07
ATE82502T1 (de) 1992-12-15
EP0251134A3 (en) 1989-05-03
NO872675D0 (no) 1987-06-25
AU608228B2 (en) 1991-03-28

Similar Documents

Publication Publication Date Title
DK169422B1 (da) Anvendelse af heparin, N-desulfateret, N-acetyleret heparin eller O-desulfateret, N-acetyleret heparin til fremstilling af et farmaceutisk præparat, som er effektivt over for autoimmune sygdomme, til lindring af sådanne sygdomme og til behandling af autoimmune sygdomme i pattedyr, herunder mennesker, og til hindring eller forsinkelse af allotransplantatudstødelse
Strom et al. The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity
Osman et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α‐galactosylceramide
Bennett et al. Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells.
Rolls et al. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation‐associated neurodegeneration
DE60026561T2 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
Hammond et al. NKT cells: potential targets for autoimmune disease therapy?
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DE69723888T2 (de) Gemischter Chimerismus und Toleranz
US6013641A (en) Use of hyaluronic acid as an immunosuppressant
JP2011037865A (ja) 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物
CZ232593A3 (en) Pharmaceutical preparation for preventing and/or therapy of pathological states
Irintchev et al. Cellular and molecular reactions in mouse muscles after myoblast implantation
US5206223A (en) Method for inhibiting heparanase activity
DE10231655A1 (de) Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
JPH05508663A (ja) 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物
Fortier Studies on the control of ACTH release by means of hypophyseal transplants
Horsburgh et al. Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes
EP0598032A4 (de) Behandlung für diabetes vom type-ii.
Silvers et al. Studies on the immunotherapy of runt disease in rats
Van Wijmeersch et al. Autologous and allogeneic hematopoietic stem cell transplantation for multiple sclerosis: perspective on mechanisms of action
Klein Jr Effect of spleen cells on cytotoxicity by immune lymph node cells: cell-mediated immune suppression (? enhancement) in vitro
US20030091541A1 (en) Method of inducing immunotolerance in an organ transplantation recipient
Ross Smooth muscle cell and atherosclerosis
CA1318591C (en) Composition containing heparin or derivative thereof

Legal Events

Date Code Title Description
A0 Application filed
B1 Patent granted (law 1993)
PBP Patent lapsed